For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

This is the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and ...

The Clearblue® Menopause Stage Indicator - launched in August 2023 - is the first product to combine a woman's urine FSH results with her age and cycle history to determine her likely menopause stage ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Just type in #weightloss on any social media platform today and you'll be met with everything from intermittent fasting diets ...

Kwame Raoul’s office sent cease and desist letters to five unnamed medical spas in the Chicago area that were allegedly ...

Glaswegian cosmetic practitioner Awfa Paulina said weight-loss drugs can be 'effective tools', but that no guarantees can be ...